FIELD: medicine.
SUBSTANCE: method involves administering vitaminotherapy. Peptide bioregulator of Retinalamine is additionally introduced at a dose of 5 mg every other day in inactive tuberculous inflammation phase. The total treatment course is 10 procedures long.
EFFECT: activated mediatory interaction between retinal cells; intensified oxygen supply; retained or increased vision acuity.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF TUBERCULOSIS UVEITIS | 2004 |
|
RU2290191C2 |
| METHOD OF TREATING CHORIORETINAL DYSTROPHIES AFTER TUBERCULOSIS CHORIORETINITIS | 2009 |
|
RU2463998C2 |
| REGENERATING RESOLVENT AND WAYS OF TREATMENT BY MEANS OF THIS AGENT | 2007 |
|
RU2362554C2 |
| METHOD FOR TREATING DYSTROPHIC DISEASES OF EYES | 2000 |
|
RU2195297C2 |
| METHOD FOR TREATING SLOW CHRONIC TUBERCULAR UVEITIS | 2004 |
|
RU2283132C2 |
| AGENT RECOVERING RETINA EYE FUNCTION | 1993 |
|
RU2073518C1 |
| TETRAPEPTIDE STIMULATING EYE RETINA FUNCTION, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD OF ITS USING | 2000 |
|
RU2161982C1 |
| METHOD FOR DIAGNOSING EYE FUNDUS DISEASES | 2005 |
|
RU2316994C2 |
| AGENT INHIBITING ANGIOGENESIS IN VISUAL ORGAN DISEASE | 2001 |
|
RU2177801C1 |
| METHOD OF TREATING DISEASES OF OPTIC NERVE AND RETINA | 2008 |
|
RU2373904C1 |
